Toyota|$17.69 (¥2,828)+1.25%▲ (in JPY terms)
Sony|$27.23 (¥4,353)+1.68%▲ (in JPY terms)
SoftBank|$22.18 (¥3,547)-5.11%▼ (in JPY terms)
MUFG|$21.73 (¥3,475)-0.66%▼ (in JPY terms)
Keyence|$466.45 (¥74,580)-0.60%▼ (in JPY terms)
Nintendo|$54.87 (¥8,773)+2.45%▲ (in JPY terms)
NTT|$1.05 (¥168)+0.54%▲ (in JPY terms)
Takeda|$43.32 (¥6,926)+1.48%▲ (in JPY terms)
Tokyo Electron|$59.17 (¥9,461)+1.69%▲ (in JPY terms)
Recruit|$109.83 (¥17,560)+5.06%▲ (in JPY terms)
ITOCHU|$15.09 (¥2,412)-0.02%▼ (in JPY terms)
Honda|$11.52 (¥1,842)+1.66%▲ (in JPY terms)
Shin-Etsu|$35.67 (¥5,704)-1.50%▼ (in JPY terms)
Tokio Marine|$3.73 (¥597)+0.56%▲ (in JPY terms)
Fast Retailing|$513.61 (¥82,120)+2.41%▲ (in JPY terms)
Toyota|$17.69 (¥2,828)+1.25%▲ (in JPY terms)
Sony|$27.23 (¥4,353)+1.68%▲ (in JPY terms)
SoftBank|$22.18 (¥3,547)-5.11%▼ (in JPY terms)
MUFG|$21.73 (¥3,475)-0.66%▼ (in JPY terms)
Keyence|$466.45 (¥74,580)-0.60%▼ (in JPY terms)
Nintendo|$54.87 (¥8,773)+2.45%▲ (in JPY terms)
NTT|$1.05 (¥168)+0.54%▲ (in JPY terms)
Takeda|$43.32 (¥6,926)+1.48%▲ (in JPY terms)
Tokyo Electron|$59.17 (¥9,461)+1.69%▲ (in JPY terms)
Recruit|$109.83 (¥17,560)+5.06%▲ (in JPY terms)
ITOCHU|$15.09 (¥2,412)-0.02%▼ (in JPY terms)
Honda|$11.52 (¥1,842)+1.66%▲ (in JPY terms)
Shin-Etsu|$35.67 (¥5,704)-1.50%▼ (in JPY terms)
Tokio Marine|$3.73 (¥597)+0.56%▲ (in JPY terms)
Fast Retailing|$513.61 (¥82,120)+2.41%▲ (in JPY terms)

2026-08-17 DAIICHI SANKYO COMPANY,LIMITED “An announcement regarding the approval of Enhertu® and pertuzumab combination therapy for first-line treatment of HER2-positive breast cancer in China (264KB) will open in a new window as a PDF file.”

2026-08-17 DAIICHI SANKYO COMPANY,LIMITED “An announcement regarding the approval of Enhertu® and pertuz … 続きを読む

2026-08-17 DAIICHI SANKYO COMPANY,LIMITED “The results of the Phase 3 clinical trial of trastuzumab deruxtecan (T-DXd/DS-8201) for the first-line treatment of non-small cell lung cancer with HER2 gene mutations (270.9KB) will be displayed in a new window as a PDF file.”

2026-08-17 DAIICHI SANKYO COMPANY,LIMITED “The results of the Phase 3 clinical trial of trastuzumab deru … 続きを読む